PPI use in the study population increased steadily from 1999 to 2004. These data offer valuable information on current PPI dosing patterns that may be used to design future clinical trials for assessment of gastroesophageal reflux disease regimens and clinical outcomes in the infant population.

No abstract

Background: Aspirin challenge and desensitization remains the gold standard in diagnosis and treatment for patients with aspirin-exacerbated respiratory disease (AERD), but the protocols can be time and resource intensive. Objective: To provide evidence that oral aspirin challenge and desensitization can be safely performed in an outpatient setting in one day. Methods: Forty-four patients with a confirmed diagnosis of AERD, stable asthma and baseline FEV1 ≥70% of predicted, completed an oral aspirin challenge and desensitization protocol. The starting dose was 40.5mg with escalating doses of aspirin (81, 162.5, 325mg) at 90-minute intervals until symptoms were provoked. Desensitization was defined as tolerating a repeated administration of the provocative aspirin dose and at least one subsequent dose, bringing the total aspirin ingested during the in-clinic desensitization to ≥325mg. Results: Ninety-three percent of patients completed the challenge and desensitization in one day, with an average protocol completion time of 9 hours and 29 minutes. Two patients (4.6%) chose to complete the protocol over two days. One patient (2.3%) was discontinued from the protocol due to ongoing abdominal discomfort and diarrhea. No patient required epinephrine, emergency department visit or hospitalization.